文献速递肾癌与肾肿瘤

透明细胞肾细胞癌中复发性异常剪接变异的蛋白质基因组学、表观遗传学及临床意义

Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma.
PubMed 文献 · Eur Urol · 2022-06-17

研究利用癌细胞系百科全书的RNA测序数据识别透明细胞肾细胞癌中独特表达的新连接,并在正常组织及多个肿瘤队列中验证候选剪接变异。研究识别出16个透明细胞肾细胞癌富集的剪接变异,其中部分与基因特异性CpG甲基化负相关,并基于5个剪接变异的表达构建了生存风险评分,该评分在多队列多因素分析中一致且适用。

要点

  • 研究识别出16个透明细胞肾细胞癌富集的异常剪接变异。
  • 基于RNASET2、FGD1、PDZD2、COBLL1和PTPN14五个剪接变异表达构建的生存风险评分在多队列多因素分析中一致且适用。
  • 高风险组中调节HIF-1α剪接的剪接因子RBM4蛋白表达显著降低。

核心结论

  • 研究描述了16个透明细胞肾细胞癌富集的异常剪接变异,其中许多与疾病生物学和/或临床结局相关。
  • 本研究提供了一种识别和表征疾病特异性异常剪接变异的新策略。

研究设计与样本

  • 利用癌细胞系百科全书的RNA测序数据识别透明细胞肾细胞癌中独特表达的新连接。
  • 候选剪接变异在基因型-组织表达项目的正常组织及癌症基因组图谱、临床蛋白质组肿瘤分析联盟和本机构Total Cancer Care数据库的原发肿瘤组织中检查表达。
  • 所有队列均有临床病理、基因组和生存数据;癌症基因组图谱和临床蛋白质组肿瘤分析联盟队列有表观遗传数据;临床蛋白质组肿瘤分析联盟队列有蛋白质组数据。

主要发现

  • 研究流程识别出16个透明细胞肾细胞癌富集的剪接变异。
  • EGFR、HPCAL1-SV和RNASET2-SV表达与基因特异性CpG甲基化负相关。
  • 基于RNASET2、FGD1、PDZD2、COBLL1和PTPN14五个剪接变异表达构建的生存风险评分在多队列多因素分析中一致且适用。
  • 在高风险组(由基于剪接变异的评分定义)中,调节HIF-1α剪接的剪接因子RBM4在蛋白质水平表达显著降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alternative mRNA splicing can be dysregulated in cancer, resulting in the generation of aberrant splice variants (SVs). Given the paucity of actionable genomic mutations in clear cell renal cell carcinoma (ccRCC), aberrant SVs may be an avenue to novel mechanisms of pathogenesis. OBJECTIVE: To identify and characterize aberrant SVs enriched in ccRCC. DESIGN, SETTING, AND PARTICIPANTS: Using RNA-seq data from the Cancer Cell Line Encyclopedia, we identified neojunctions uniquely expressed in ccRCC. Candidate SVs were then checked for expression across normal tissue in the Genotype-Tissue Expression Project and primary tumor tissue from The Cancer Genome Atlas (TCGA), Clinical Proteomic Tumor Analysis Consortium (CPTAC), and our institutional Total Cancer Care database. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Clinicopathologic, genomic, and survival data were available for all cohorts. Epigenetic data were available for the TCGA and CPTAC cohorts. Proteomic data were available for the CPTAC cohort. The association of aberrant SV expression with these variables was examined using the Kruskal-Wallis test, pairwise t test, Spearman correlation test, and Cox regression analysis. RESULTS AND LIMITATIONS: Our pipeline identified 16 ccRCC-enriched SVs. EGFR, HPCAL1-SV and RNASET2-SV expression was negatively correlated with gene-specific CpG methylation. We derived a survival risk score based primarily on the expression of five SVs (RNASET2, FGD1, PDZD2, COBLL1, and PTPN14), which was consistent and applicable across multiple cohorts on multivariate analysis. The splicing factor RBM4, which modulates splicing of HIF-1α, exhibited significantly lower expression at the protein level in the high-risk group, as defined by our SV-based score. CONCLUSIONS: We describe 16 aberrant SVs enriched in ccRCC, many of which are associated with disease biology and/or clinical outcomes. This study provides a novel strategy for identifying and characterizing disease-specific aberrant SVs. PATIENT SUMMARY: We describe a method to identify disease targets and biomarkers using transcriptomic analysis beyond somatic mutations or gene expression. Kidney tumors express unique splice variants that may provide additional prognostic information following surgery.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Chang A, Chakiryan NH, Du D, et al. Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma. Eur Urol. 2022. PMID: 35718636. doi:10.1016/j.eururo.2022.05.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。